NCT05098574View on ClinicalTrials.gov

Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Premenstrual Dysphoric DisorderBipolar Disorder
Interventions
DRUG

Yaz

Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks

DRUG

Placebo

Appearance, packaging, and labeling of placebo will be matched to their active counterpart.

Trial Locations (1)

L8N 3K7

St Joseph's Healthcare Hamilton, Hamilton

All Listed Sponsors
collaborator

Hamilton Academic Health Sciences Organization

OTHER

collaborator

McMaster University

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER